Furthermore, knockdown of CPA4 abolished the ability of cells to develop xenograft tumor, suggesting that CPA4 stimulates the progression of thyroid cancer by mediating interactions between M2 macrophages and ATC cells and CPA4 can be a new therapeutic target for the treatment of patients with ATC. Here, CPA4 is linked to thyroid gland carcinoma.